1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Praxis Pushes Ulixacaltamide Into Phase III For Essential Tremor, But Uncertainty Remains

 
• By Alaric DeArment

Praxis hopes to initiate a Phase III later in 2023, but an analyst said it is unclear if regulators will align with the company on a proposed primary endpoint.

Praxis announced results from its Phase II study in essential tremor • Source: Shutterstock

Praxis Precision Medicines, Inc. plans to move ulixacaltamide for essential tremor into Phase III development after announcing mixed results from the Phase IIb Essential1 trial, meaning it has found some success in shifting its R&D focus after a study of its drug for depression failed in 2022. But some uncertainty remains about the proposed primary endpoint for the ulixacaltamide Phase III trial based on its communication with US regulators.

The company said 3 March that the results of Essential1 showed a numerical improvement in the primary endpoint of modified...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D